KCT0006987招募中未知
A 12-week, Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of KBL982 on Improving Alcoholic Liver Dysfunction
Kobiolabs0 个研究点目标入组 105 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 75?(Year)（—）
- 性别
- All
入选标准
- •1) Males and females aged over 19 years, under 75 years at the screening examination
- •2) Participants who exceeds the upper limit and is within three times the upper limit
- •3) Participants who consume alcohol more than 20g/day for men and 10g/day for women
- •4) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions
排除标准
- •1) Those who are hospitalized, mediated, and rehabilitated due to heart disease and central neurological disorders.
- •2) Those who have severe alcohol use disorders based on DSM-V.
- •3) Patients with cirrhosis or liver cancer according to abdominal ultrasonography based on visit 2
- •4) Those who have received chemotherapy or are being treated for malignant tumors other than basal cell carcinoma and squamous cell carcinoma (restrained non-invasive lesions) or those who have been cured of cancer for less than 5 years.
- •5) Those whose AST (GOT) or ALT (GPT) is 5 times or more of the normal upper limit of the implementation engine.
- •6) A person whose ALP is three times or more than the normal upper limit of the implementation engine, whose platelet is 105/µL or less, or whose AFP is more than 10 ng/mL.
- •7) In Visit 1, a positive factor for HBs Ag or HCV Ab test.
- •8) less than 3 g/dL of albumin or greater than 3 mg/dL of total bilirubin.
- •9) Those whose creatine is 1.5 times or more than the upper limit of normal range
- •10) Uncontrolled thyroid disease patients.
- •11) Those who took drugs that affect liver function within 4 weeks of visit 1 (anti-tuberculosis, anticonvulsant, gout therapy, antidepressant, and other drugs that may cause hepatotoxicity).
- •12) Within 4 weeks of visit 1, Those who took Biphenyl Dimethyl Dicarboxylate, Cholagues, cholelitholytics, Antidotes, Detoxifying Agents & Drugs Used in Substance Defense.
- •13) Those who took NSAIDs, antiviral drugs, and antibiotics within 2 weeks of visit 1.
- •14) A person who took herbal medicine, Vit.E supplementation (800 IU or more), or health functional foods related to liver function improvement within 2 weeks of visit 1.
- •15) Those who have consumed probiotics health functional foods and foods containing lactobacillus continuously (more than four times a week) within two weeks of visiting 1.
- •16) Those who took adrenocortical hormones, sex hormones, or those who underwent hormone replacement therapy (HRT) within 4 weeks of visit 1.
- •17) Uncontrolled hypertensive patients (measurement criteria after stabilization of 10 minutes of subjects subject to human application test with systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher)
- •18) Uncontrolled diabetic patients (if they start a new drug or have a dose change due to diabetes within 3 months or 180 mg/dL of fasting blood sugar, or if they receive insulin).
- •19) A person who received a new antiphospholipid-based drug within 3 months of visit 1 (if administered without a change in dose from 3 months ago, he/she can participate)
- •20) A person who has been newly administered with a vitamin B complex drug (UDCA: Ursodocy Cholic Acid, Silymarin, etc.) within 3 months of visit 1 (if administered without any change in dose from 3 months ago, he/she can participate)
- •21) A person who complains of severe gastrointestinal symptoms such as heartburn and indigestion and has a problem in eating food for human application tests.
- •22) Those who are sensitive or allergic to food ingredients for this human application test.
- •23) A person who is pregnant or has plans to become pregnant during the human body application test.
- •24) Those who participated in other interventional clinical trials (including human application trials) within 1 month of visit 1, or who plan to participate in other interventional clinical trials (including human application trials) after the start of this human application trial.
研究者
相似试验
进行中（未招募）
3 期
A 12 Week study to assess Safety & efficacy of QAW039 when added to standard of care in patients with uncontrolled asthmaCTRI/2018/06/014543ovartis Healthcare Pvt Ltd
已完成
2 期
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients => 18 Years of Age With Severe Uncontrolled Asthma.AsthmaJPRN-jRCT2080225330ovartis Pharma. K.K.625
已完成
2 期
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresCTRI/2010/091/001213ovartis Health care Private Limited126
进行中（未招募）
不适用
A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of MPCO on Mild Cognitive ImpairmentKCT0008219INE B150
招募中
不适用
A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of DKB-140 on Gingival HealthKCT0009501Dong Kook Pharm120